LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Ramalingam SCHIH-HSIN YANGLee C.KKurata TKim D.-WJohn TNogami NOhe YJänne P.A.2020-05-262020-05-2620161556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995428398&doi=10.1016%2fS1556-0864%2816%2930324-0&partnerID=40&md5=382c85073757c07a5fe44a9d9ff43993https://scholars.lib.ntu.edu.tw/handle/123456789/494981[SDGs]SDG3epidermal growth factor receptor; osimertinib; advanced cancer; adverse event; adverse outcome; Article; Asian; cohort analysis; controlled clinical trial; controlled study; diarrhea; drug dose reduction; drug efficacy; drug safety; EGFR gene; exon; female; follow up; gene deletion; gene mutation; human; major clinical study; male; mutational analysis; non small cell lung cancer; outcome assessment; overall survival; paronychia; phase 1 clinical trial; priority journal; progression free survival; stomatitis; treatment duration; treatment responseLBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohortsjournal article10.1016/S1556-0864(16)30324-02-s2.0-84995428398